EGFR and non-small cell lung carcinoma: This strategy might be useful for NSCLC therapy because an HDAC inhibitor, MPT0E028, enhanced erlotinib-induced cell death in epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI)-resistant NSCLC cells [61] and SAHA, a HDAC inhibitor, had profound anti-growth activity against NSCLC cells [62].